Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: out_of_the_loop who wrote (2096)	1/30/2000 1:07:00 AM
From: Mike M	Read Replies (1) \| Respond to of 5582

Anyway, my point is that something favorable could be worked out if an offer were made - such as a spinoff of one of the ventures. We discussed that possibility a long time ago but nobody has talked about it much lately. Exactly. A means to purchase the 40% of Gel Tech they don't own would be through a 10% (for instance) spin off. Say they issued 4M shares of Gel Tech to current shareholders one per two GUMM shares owned at a price of $15/share. A portion of the proceeds could then pay BioDeliveries for their share of Gel Tech. What do you suppose the demand would be for a Gel Tech IPO if, for instance, Zicam sales for 99 were $10M and yr 2000 came in at say $50M?